Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.
Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the adverse events (AEs) that can occur from nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for patients with melanoma.
The most common AEs include skin rash, endocrine toxicities, and are gastrointestinal-related. These therapies that are often used in melanoma can affect any organ and physicians should be aware of pneumonitis, nephritis, arthralgia, myositis, and central nervous system toxicities, says Sznol. Liver function test elevation and endocrinopathies, such as thyroiditis and pituitary dysfunction, can also occur.
These AEs are important to note when patients are receiving an anti—PD-1 agent in combination with an anti–CTLA-4 agent, Sznol concludes.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
2 Commerce Drive
Cranbury, NJ 08512